OpenEvidence AI startup hits $15B valuation as US doctors use tool
The ad-supported medical AI platform has reached a $15 billion valuation after nearly two-thirds of US physicians began using its chatbot.
Key points
- OpenEvidence reached a $15 billion valuation in September after raising $250 million.
- Nearly two-thirds of US doctors use the platform, generating over 42 million prompts last month.
- The company projects $400 million to $500 million in ad revenue by the end of 2026.
Miami-based OpenEvidence has achieved a $15 billion valuation, according to a report by Ars Technica. The startup, founded by Daniel Nadler in 2022, closed a $250 million funding round in September. This latest investment round values the company at $15 billion, reflecting its rapid expansion in the healthcare technology sector.
Nearly two-thirds of US physicians are using OpenEvidence to assist with patient decisions, Ars Technica reported. The company stated that its users processed more than 42 million prompts last month. Doctors use the chatbot to search medical journals and clinical guidelines for diagnostic and treatment support.
Market Growth and Financials
OpenEvidence has attracted nearly $1 billion in investment over the past 18 months, according to Ars Technica. Backers include Andreessen Horowitz, Blackstone, Thrive Capital, and Sequoia. The company operates as an ads-powered platform. A source close to the company indicated that OpenEvidence booked $100 million in ad commitments for 2025.
The startup is projected to generate between $400 million and $500 million in advertising revenue by the end of 2026, the source added. This financial trajectory supports the company's high valuation despite operating in a sector traditionally slow to adopt generative AI tools. The growth has been driven largely by word of mouth among medical professionals.
Clinical Adoption and Scrutiny
Medical professionals have praised OpenEvidence for easing workloads, according to interviews with eight senior physicians cited by Ars Technica. The platform distinguishes itself by focusing on peer-reviewed sources, including the New England Journal of Medicine and the Journal of the American Medical Association. This curated source list is central to the company's value proposition for clinicians seeking reliable information.
However, the tool faces scrutiny from researchers concerned about the accuracy of its results, according to the report. As doctors grow more dependent on the AI for treatment decisions, questions about reliability have emerged. Large AI companies like OpenAI and Anthropic are also entering the space, posing a competitive threat to OpenEvidence's market position.
What should you do?
Healthcare organizations should evaluate the accuracy of AI-generated medical information before clinical adoption. Institutions should monitor for discrepancies between AI outputs and established clinical guidelines. Professionals should verify critical diagnostic suggestions through primary peer-reviewed sources.
Background: Generative AI
Generative AI examples include text completion, image synthesis and code generation. These systems predict the next likely token based on vast training datasets. Understanding the underlying mechanics helps you identify risks like data leakage and hallucination in your infrastructure.
Read the full guide: Generative AI Examples: Mechanisms, Risks and Control
What to do and how to stay safe: OpenEvidence
- Verify AI-generated medical recommendations against primary peer-reviewed journals and clinical guidelines.
- Monitor internal usage metrics to identify potential over-reliance on automated diagnostic suggestions.
- Review vendor data privacy policies to ensure patient information remains secure during processing.
- Assess the accuracy of AI outputs through regular auditing and clinical validation protocols.
Step-by-step guide: Prompt Injection Warning Signs: How to Spot AI Manipulation
General security guidance from the Threat Times newsroom. It is not confirmed advice from the organisations named in this story.
Frequently asked questions
How much funding has OpenEvidence raised?
OpenEvidence has raised nearly $1 billion in the past 18 months, including a $250 million round in September.
Who are the investors in OpenEvidence?
Investors include Andreessen Horowitz, Blackstone, Thrive Capital, and Sequoia, according to Ars Technica.
What sources does OpenEvidence use?
The platform focuses on peer-reviewed journals such as the New England Journal of Medicine and the Journal of the American Medical Association.
